Journal
CURRENT MEDICINAL CHEMISTRY
Volume 22, Issue 35, Pages 4104-4117Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867322666151002112256
Keywords
Hippo; TAZ; TEAD; Verteporfin; VGLL4; YAP
Funding
- NSFC [31571479]
Ask authors/readers for more resources
The Hippo signaling pathway is critical in regulating tissue homeostasis, organ size, and tumorigenesis. YAP and TAZ, two major effectors of the Hippo pathway, function as transcriptional co-activators and promote target gene expression mainly through interaction with TEAD family transcription factors. As oncoproteins, YAP and TAZ are frequently activated or highly expressed in various cancer specimens. Moreover, their activity has been linked to resistance to a few widely used anti-cancer drugs, and YAP activation contributes to cancer relapse. Thus, the Hippo pathway, especially YAP/TAZ-TEAD interaction, represents an attractive target for anti-cancer therapies. Here, we will discuss potential approaches to inhibit YAP/TAZ activity, and also review currently available small molecules targeting the Hippo pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available